Phase 2a Randomized, Single-Blind, Placebo-Controlled, 24-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Osteosynthesis Sites

Trial Profile

Phase 2a Randomized, Single-Blind, Placebo-Controlled, 24-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Osteosynthesis Sites

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs MBN 101 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions
  • Sponsors Microbion Corporation
  • Most Recent Events

    • 14 Feb 2017 Planned number of patients changed from 36 to 24.
    • 16 Jun 2016 According to a Microbion Corporation media release, this study is partially funded by a grant #W81XWH-12-2-0100 from the U.S. Department of Defense (DOD), Military Infectious Diseases Research Program and managed by the University of Pennsylvania.
    • 16 Jun 2016 According to a Microbion Corporation media release, first patient in this trial has been enrolled at Thomas Jefferson Hospital in Philadelphia, Pennsylvania.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top